版本:
中国

BRIEF-Fda confirms Prometic's PBI-4050 IPF clinical trial design

April 18 Prometic Life Sciences Inc

* FDA confirms Prometic's PBI-4050 IPF clinical trial design

* Prometic Life Sciences Inc - Prometic to also conduct placebo controlled phase 2/3 PBI-4050 monotherapy clinical trial

* Prometic Life Sciences Inc - FDA concurs with add-on placebo controlled phase 2/3 clinical trial for PBI-4050 in combination with Nintedanib Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐